Halozyme Therapeutics, Inc. (NASDAQ:HALO) headquartered in San Diego, will host a conference call for the investment community to discuss the 2Q20 financial results on 10th August 2020 at 4:30 PM Eastern Time.
The conference call will also be webcast live under the investor relations section of the website www.halozyme.com
Earnings Expectation
Halozyme Therapeutics, Inc. is reporting second quarter earnings results on Monday 10th August 2020, after market close. The consensus estimates from Thomson Reuters are income of $ 0.25 per share. For the full year, analysts predict revenues of $ 234.80 million, while looking forward to income of $ 0.77 per share.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 230.00 million ~ $ 245.00 million, where as bottomline are predicted in a range of $ 0.60 ~ $ 0.75 per share
Click Here For More Historical Outlooks Of Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc., a biotechnology company, engages in researching, developing, and commercializing novel oncology therapies in the United States, Switzerland, and internationally. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit. The companys products are based on the Enhanze technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.
